AU2287499A - Azetidinecarboxamide derivatives for treating cns disorders - Google Patents

Azetidinecarboxamide derivatives for treating cns disorders

Info

Publication number
AU2287499A
AU2287499A AU22874/99A AU2287499A AU2287499A AU 2287499 A AU2287499 A AU 2287499A AU 22874/99 A AU22874/99 A AU 22874/99A AU 2287499 A AU2287499 A AU 2287499A AU 2287499 A AU2287499 A AU 2287499A
Authority
AU
Australia
Prior art keywords
cns disorders
treating cns
azetidinecarboxamide
derivatives
azetidinecarboxamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22874/99A
Other languages
English (en)
Inventor
David Reginald Adams
Corinna Dagmar Bodkin
Ian Anthony Cliffe
Howard Langham Mansell
Nathaniel Julius Monck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Cerebrus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801500.1A external-priority patent/GB9801500D0/en
Priority claimed from GBGB9824457.7A external-priority patent/GB9824457D0/en
Application filed by Cerebrus Pharmaceuticals Ltd filed Critical Cerebrus Pharmaceuticals Ltd
Publication of AU2287499A publication Critical patent/AU2287499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU22874/99A 1998-01-23 1999-01-22 Azetidinecarboxamide derivatives for treating cns disorders Abandoned AU2287499A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9801500 1998-01-23
GBGB9801500.1A GB9801500D0 (en) 1998-01-23 1998-01-23 Chemical compounds - II
GB9824457 1998-11-06
GBGB9824457.7A GB9824457D0 (en) 1998-11-06 1998-11-06 Chemical compounds II
PCT/GB1999/000219 WO1999037612A1 (en) 1998-01-23 1999-01-22 Azetidinecarboxamide derivatives for treating cns disorders

Publications (1)

Publication Number Publication Date
AU2287499A true AU2287499A (en) 1999-08-09

Family

ID=26313010

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22874/99A Abandoned AU2287499A (en) 1998-01-23 1999-01-22 Azetidinecarboxamide derivatives for treating cns disorders

Country Status (10)

Country Link
US (1) US6403574B1 (enExample)
EP (1) EP1049672B1 (enExample)
JP (1) JP4542263B2 (enExample)
AT (1) ATE250027T1 (enExample)
AU (1) AU2287499A (enExample)
DE (1) DE69911373T2 (enExample)
DK (1) DK1049672T3 (enExample)
ES (1) ES2207171T3 (enExample)
PT (1) PT1049672E (enExample)
WO (1) WO1999037612A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
AU2004234125A1 (en) * 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
US20060276452A1 (en) * 2003-05-01 2006-12-07 Vernalis Research Limited Use of azetidinecarboxamide derivatives in therapy
EP1618105A1 (en) * 2003-05-01 2006-01-25 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
US11141404B1 (en) * 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872447A (en) 1958-12-23 1961-07-12 Lepetit Spa 1-carbamyl-3-substituted azetidines
US4226861A (en) 1978-04-18 1980-10-07 A. H. Robins Company, Inc. N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
IL68699A (en) * 1982-08-19 1986-08-31 Robins Co Inc A H 3-phenoxy-1-azetidine-carboxamides,their preparation and pharmaceutical compositions containing them
US4505907A (en) 1982-09-02 1985-03-19 A. H. Robins Company, Inc. N-Formyl and N-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides
IE58943B1 (en) * 1985-02-28 1993-12-01 Robins Co Inc A H 3-Aryloxy-azetidine-carboxamides
US4956359A (en) * 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics

Also Published As

Publication number Publication date
JP4542263B2 (ja) 2010-09-08
DE69911373D1 (de) 2003-10-23
PT1049672E (pt) 2004-02-27
DK1049672T3 (da) 2004-01-19
ES2207171T3 (es) 2004-05-16
EP1049672A1 (en) 2000-11-08
WO1999037612A1 (en) 1999-07-29
ATE250027T1 (de) 2003-10-15
US6403574B1 (en) 2002-06-11
JP2002501045A (ja) 2002-01-15
DE69911373T2 (de) 2004-07-01
EP1049672B1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
PH31123A (en) Benzimidazole compounds.
NZ331452A (en) use of 2-(4-indolyl-1-piperazinyl)alkylene-N-(2-pyridyl)-cyclohexane- carboxamide derivatives in treating central nervous system disorders
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
PL341514A1 (en) Substituted compounds of 2-benzylamino-2-phenyl acetamide
HU912786D0 (en) Process for producing 4-substituted-dihydro-pyrido(4,3-d) pyrimidine derivatives as well as pharmaceutical preparatives containing said compounds
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
AU3386299A (en) N-aryloxyethylamine derivatives for the treatment of depression
UA66888C2 (uk) 3-тетрагідропіридин-4-іл індоли, спосіб їх отримання та спосіб лікування психічних розладів
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU640590B2 (en) 3-(1h-indazol-3-yl)-4-pyridinamines
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
IL131380A0 (en) The use of a compound for the manufacture of a pharmaceutical preparatin for the treatment or prevention of prostate cancer
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
MXPA02011966A (es) Derivados de higromicina a para el el tratamiento de infecciones bacterianas y por protozoarios.
AU3479299A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
PH30180A (en) Leustroducsin h its preparation and its therapeutic use
MX9705379A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis vasodilatadora.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase